WallStreetZenWallStreetZen

NASDAQ: LIMN
Liminatus Pharma Inc Stock Ownership - Who owns Liminatus Pharma?

OverviewEarningsRevenueDividendOwnership

Insider buying vs selling

Have Liminatus Pharma Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when LIMN insiders and whales buy or sell their stock.

LIMN Shareholders

What type of owners hold Liminatus Pharma Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Chris Kim23.72%6,169,406$36.58MInsider
Valetudo Therapeutics LLC23.72%6,169,406$36.58MInsider
Kh Feelux Co Ltd15.38%4,000,000$23.72MInsider

1 of 1

LIMN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
LIMN0.00%62.81%
CTNM58.45%10.44%Net Buying
LXEO79.72%20.28%Net BuyingNet Selling
PBYI58.34%41.66%Net SellingNet Selling
ENTA56.75%43.25%Net Selling
View Top Biotech Stocks

Liminatus Pharma Stock Ownership FAQ

Who owns Liminatus Pharma?

Liminatus Pharma (NASDAQ: LIMN) is owned by 0.00% institutional shareholders, 62.81% Liminatus Pharma insiders, and 37.19% retail investors. Chris Kim is the largest individual Liminatus Pharma shareholder, owning 6.17M shares representing 23.72% of the company. Chris Kim's Liminatus Pharma shares are currently valued at $36.58M.

If you're new to stock investing, here's how to buy Liminatus Pharma stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.